Description
The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It cell line is advisable to keep a backup culture which is not drug-challenged.
Adherent Suspension
Suspension
Suggested Medium
RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1µM Daunorubicin
Quality Control
Pr8/22 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
Pr8/22 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
Pr8/22 Cell Line is for research use only
